Here, we show that serum LPS, LBP, and I-FABP levels, markers of gut damage and permeability, are raised in active RA patients compared to healthy controls and that these measures are independent from the treatment, implying that enhanced permeability is a feature of disease rather than of therapy. The gene discussed is FABP2; the disease is rheumatoid arthritis.